What does PHARMACIE PHARMAVIE LE ROEULX do?

PHARMACIE PHARMAVIE LE ROEULX is a pharmacy in Le Roeulx. Private Limited, started on 23 October 2001, 1 establishment.

What is the address of PHARMACIE PHARMAVIE LE ROEULX?

The registered office of PHARMACIE PHARMAVIE LE ROEULX is located at Rue Emile Vandervelde(R) 9, 7070 Le Roeulx.

Is PHARMACIE PHARMAVIE LE ROEULX still active?

Yes. According to the CBE (16 September 2026) PHARMACIE PHARMAVIE LE ROEULX is active, legal situation “Normale toestand”, started on 23 October 2001.

Is PHARMACIE PHARMAVIE LE ROEULX registered on Peppol?

Yes, PHARMACIE PHARMAVIE LE ROEULX is registered on the Peppol network with ID 0208:0475920503.

What is the enterprise number of PHARMACIE PHARMAVIE LE ROEULX?

The enterprise number of PHARMACIE PHARMAVIE LE ROEULX is BE0475920503.

When was PHARMACIE PHARMAVIE LE ROEULX founded?

PHARMACIE PHARMAVIE LE ROEULX was founded on 23 October 2001.

Who are the directors of PHARMACIE PHARMAVIE LE ROEULX?

According to the 2025 annual accounts, the directors of PHARMACIE PHARMAVIE LE ROEULX are: PHARMACIE BLONDEAU - VANDER CASSYEN SRL, MATHIEU BLONDEAU.

Is PHARMACIE PHARMAVIE LE ROEULX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 October 2001; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMACIE PHARMAVIE LE ROEULX make in 2025?

PHARMACIE PHARMAVIE LE ROEULX posted a profit after taxes of € 41,538 in financial year 2025.

What is the revenue of PHARMACIE PHARMAVIE LE ROEULX?

As a small company, PHARMACIE PHARMAVIE LE ROEULX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 290,605.

How much does an employee at PHARMACIE PHARMAVIE LE ROEULX earn?

The average wage cost per full-time employee at PHARMACIE PHARMAVIE LE ROEULX was € 45,700 in 2025: staff costs of € 200,906 for 4.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMACIE PHARMAVIE LE ROEULX have?

According to the 2025 annual accounts, PHARMACIE PHARMAVIE LE ROEULX has 4.4 full-time equivalents (FTE).

PHARMACIE PHARMAVIE LE ROEULX (Private Limited)

Dossier PHARMACIE PHARMAVIE LE ROEULX, printed on 16 September 2026 from databakkes.be/en/0475920503/pharmacie-pharmavie-le-roeulx. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMACIE PHARMAVIE LE ROEULX from Le Roeulx, company number BE0475920503, closed financial year 2025 with a result of € 41,538 after tax. For that financial year PHARMACIE PHARMAVIE LE ROEULX recorded a gross margin of € 290,605 and equity of € 533,865. Compared with financial year 2024, the result moved from € 94,174 to € 41,538. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.

What it is worth Growing

€ 533,865

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 41,538

▼ 56% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 56,469

▼ 57% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 471,865.

People and assets in 2025

Full-time equivalents

4.4

▲ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 200,906

▲ 21% vs 2024

€ 45,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 16,737

▼ 35% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 80,771

▼ 20% vs 2024

€ 17,612 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 92,635

▲ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 45,405

▲ 28% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 316,541 Gross margin 2022: € 316,541 First fiscal year in the series	€ 312,116 Gross margin 2023: € 312,116 ▼ 1% vs 2022 (€ 316,541) Unfavourable step	€ 320,195 Gross margin 2024: € 320,195 ▲ 3% vs 2023 (€ 312,116) Favourable step	€ 290,605 Gross margin 2025: € 290,605 ▼ 9% vs 2024 (€ 320,195) Unfavourable step	▼ 9%
Profit after taxes	€ 68,597 Profit after taxes 2022: € 68,597 First fiscal year in the series	€ 69,262 Profit after taxes 2023: € 69,262 ▲ 1% vs 2022 (€ 68,597) Favourable step	€ 94,174 Profit after taxes 2024: € 94,174 ▲ 36% vs 2023 (€ 69,262) Favourable step	€ 41,538 Profit after taxes 2025: € 41,538 ▼ 56% vs 2024 (€ 94,174) Unfavourable step	▼ 56%
Equity	€ 328,891 Equity 2022: € 328,891 First fiscal year in the series	€ 398,154 Equity 2023: € 398,154 ▲ 21% vs 2022 (€ 328,891) Favourable step	€ 492,328 Equity 2024: € 492,328 ▲ 24% vs 2023 (€ 398,154) Favourable step	€ 533,865 Equity 2025: € 533,865 ▲ 8% vs 2024 (€ 492,328) Favourable step	▲ 8%
Total debts	€ 333,051 Total debts 2022: € 333,051 First fiscal year in the series	€ 250,684 Total debts 2023: € 250,684 ▼ 25% vs 2022 (€ 333,051) Favourable step	€ 227,084 Total debts 2024: € 227,084 ▼ 9% vs 2023 (€ 250,684) Favourable step	€ 227,237 Total debts 2025: € 227,237 Unchanged (€ 227,084) Unfavourable step
Cash	€ 128,930 Cash 2022: € 128,930 First fiscal year in the series	€ 145,401 Cash 2023: € 145,401 ▲ 13% vs 2022 (€ 128,930) Favourable step	€ 130,654 Cash 2024: € 130,654 ▼ 10% vs 2023 (€ 145,401) Unfavourable step	€ 56,469 Cash 2025: € 56,469 ▼ 57% vs 2024 (€ 130,654) Unfavourable step	▼ 57%
Land & buildings	€ 37,725 Land & buildings 2022: € 37,725 First fiscal year in the series	€ 32,457 Land & buildings 2023: € 32,457 ▼ 14% vs 2022 (€ 37,725) Unchanged	€ 28,084 Land & buildings 2024: € 28,084 ▼ 13% vs 2023 (€ 32,457) Unchanged	€ 23,832 Land & buildings 2025: € 23,832 ▼ 15% vs 2024 (€ 28,084) Unchanged	▼ 15%
Retained profit	€ 266,891 Retained profit 2022: € 266,891 First fiscal year in the series	€ 336,154 Retained profit 2023: € 336,154 ▲ 26% vs 2022 (€ 266,891) Favourable step	€ 430,328 Retained profit 2024: € 430,328 ▲ 28% vs 2023 (€ 336,154) Favourable step	€ 471,865 Retained profit 2025: € 471,865 ▲ 10% vs 2024 (€ 430,328) Favourable step	▲ 10%
Dividend	€ 25,000 Dividend 2022: € 25,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 25,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 106,396 Bank debt 2022: € 106,396 First fiscal year in the series	€ 126,881 Bank debt 2023: € 126,881 ▲ 19% vs 2022 (€ 106,396) Unfavourable step	€ 101,599 Bank debt 2024: € 101,599 ▼ 20% vs 2023 (€ 126,881) Favourable step	€ 80,771 Bank debt 2025: € 80,771 ▼ 20% vs 2024 (€ 101,599) Favourable step	▼ 20%
Balance sheet total	€ 661,942 Balance sheet total 2022: € 661,942 First fiscal year in the series	€ 648,838 Balance sheet total 2023: € 648,838 ▼ 2% vs 2022 (€ 661,942) Unchanged	€ 719,412 Balance sheet total 2024: € 719,412 ▲ 11% vs 2023 (€ 648,838) Unchanged	€ 761,102 Balance sheet total 2025: € 761,102 ▲ 6% vs 2024 (€ 719,412) Unchanged	▲ 6%
Employees (FTE)	5.4 Employees (FTE) 2022: 5.4 First fiscal year in the series	3.7 Employees (FTE) 2023: 3.7 ▼ 1.7 vs 2022 (5.4) Unchanged	3.8 Employees (FTE) 2024: 3.8 ▲ 0.1 vs 2023 (3.7) Unchanged	4.4 Employees (FTE) 2025: 4.4 ▲ 0.6 vs 2024 (3.8) Unchanged	▲ 0.6

Key figures of PHARMACIE PHARMAVIE LE ROEULX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACIE PHARMAVIE LE ROEULX?

What happened at PHARMACIE PHARMAVIE LE ROEULX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 2, 2026 New annual accounts for financial year 2025: profit of € 41,538 (▼ 56% vs 2024). Source: NBB ↗
2026 PHARMACIE BLONDEAU - VANDER CASSYEN SRL stepped down as director. NBB
2026 MATHIEU BLONDEAU stepped down as director. NBB
2020 PHARMACIE BLONDEAU - VANDER CASSYEN SRL became a director. NBB
2020 MATHIEU BLONDEAU became a director. NBB
Nov 22, 2001 New establishment in Le Roeulx. KBO
Oct 23, 2001 Start of the company according to the CBE. KBO

In short

From € 68,597 profit in 2022 to € 41,538 profit in 2025.

Paid € 95,320 in corporate taxes since 2022.

Best year ever: 2024, with € 94,174 profit.

On average € 66,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMACIE PHARMAVIE LE ROEULX? We notify you, reason included.

Follow PHARMACIE PHARMAVIE LE ROEULX

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

PHARMACIE BLONDEAU - VANDER CASSYEN 100%

The stake of PHARMACIE BLONDEAU - VANDER CASSYEN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMACIE PHARMAVIE LE ROEULX

The shares are held by PHARMACIE BLONDEAU - VANDER CASSYEN (100%).

See the full network in the app

Directors

According to the 2025 annual accounts

PHARMACIE BLONDEAU - VANDER CASSYEN SRL

Director

Also active at: PHALADEL, PHARMACIE PHARMAVIE HARCHIES, Pharmacie Pharmavie Gilly, PHARMACIE PHARMAVIE THIEU, Pharmacie GLORIEUX

since 2020 · until 2026

MATHIEU BLONDEAU

Director

since 2020 · until 2026

Shareholders

PHARMACIE BLONDEAU - VANDER CASSYEN

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Emile Vandervelde(R) 9

7070 Le Roeulx

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0475.920.503

VAT number

BE 0475.920.503

Registered office

Rue Emile Vandervelde(R) 9, 7070 Le Roeulx

Names & denominations

PHARMACIE PHARMAVIE LE ROEULX

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 October 2001

Peppol

Active · Active since 11 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMACIE PHARMAVIE LE ROEULX

Financials

What happened to PHARMACIE PHARMAVIE LE ROEULX?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions